Skip to content
MedsAcross

Medicine

Efavirenz, Lamivudine and Tenofovir disoproxil 600 mg/300 mg/300 mg tablet

Available on requestPrescription onlyUS FDAGeneric name

Efavirenz, Lamivudine and Tenofovir disoproxil 600 mg/300 mg/300 mg tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

They are available as follows: Bottles of 30 NDC 42385-928-30 Bottles of 90…

Key facts

Active ingredient (INN)
Efavirenz, Lamivudine and Tenofovir disoproxil
Brand
Sold under the generic name
Strength
600 mg/300 mg/300 mg
Dosage form
Tablet
Route
Oral
Packs
30 tablets, 90 tablets
Manufacturer
Laurus LabsIndia
Origin register
US FDA, United States
Storage
They are available as follows: Bottles of 30 NDC 42385-928-30 Bottles of 90 NDC 42385-928-90 S tore at 20° to 25°C (68° to 77°F), excursions permitted between 15° to 30°C (59° to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
14 May 2020
Identifiers
RxCUI 864661DailyMed set ID 1f8f9fe1-b8fd-4f65-8832-9d3d6802d076NDC 42385-928Application ANDA212786

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
30 tablet, film coated in 1 bottle42385-928-30Laurus LabsIndia14 May 2020
90 tablet, film coated in 1 bottle42385-928-90Laurus LabsIndia14 May 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 5 February 2018Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Efavirenz, Lamivudine and Tenofovir disoproxil 600 mg/300 mg/300 mg tablet.

Compare 1

Other strengths and forms of Efavirenz, Lamivudine and Tenofovir disoproxil

Clinical summary

Efavirenz, Lamivudine and Tenofovir disoproxil is a fixed-dose combination of a hepatitis B virus nucleoside analog reverse transcriptase inhibitor, a human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor and a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor. MedsAcross supplies Efavirenz, Lamivudine and Tenofovir disoproxil for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Efavirenz, Lamivudine and Tenofovir disoproxil

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Efavirenz, Lamivudine and Tenofovir disoproxil 600 mg/300 mg/300 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.